People who went from 7-day to 14-day dosing in pivotal trials discovered that no matter which schedule they chose, they still had an average of 0 spontaneous and joint bleeds.* That means the powerful bleed protection of IDELVION sticks around while you plan your next adventure.
*The average AsBR for people who started and stayed on 7- or 14-day prophylaxis was 0. For people who switched to prophylaxis from on-demand, the average AsBR was 0.7. AsBR=annualized spontaneous bleed rate.
Looking for the treatment that gives you more time between infusions to focus on living your life? Look no further. IDELVION is the only FDA-approved Factor IX therapy with 7- and 14-day dosing options.† This means you could infuse every other week while still maintaining high factor levels and prolonged bleed protection.
†Once well-controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
Get the elevated, sustained factor levels that meet the needs of your life. IDELVION delivered high and sustained Factor IX trough levels—20% with prophylactic use at steady-state‡ when dosed every 7 days in adults and adolescents.
‡The average dose for people receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg
§Steady-state is a consistent and uniform amount of factor in the body from continued use.
‖The average dose for children receiving prophylaxis every 7 days was 47 IU/kg.
What are factor trough levels?
Trough levels are the low point factor levels reach shortly before a new dose. Having high factor levels even at the lowest point between doses means you’re better protected from bleeds even when you’re most vulnerable.
IDELVION extends half-life using albumin fusion technology
Find support, explore your treatment options, and hear from other patients